Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) insider Oxana Beskrovnaya sold 2,153 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $11.38, for a total transaction of $24,501.14. Following the completion of the sale, the insider now directly owns 195,840 shares in the company, valued at approximately $2,228,659.20. This trade represents a 1.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Oxana Beskrovnaya also recently made the following trade(s):
- On Tuesday, February 18th, Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10.
Dyne Therapeutics Stock Performance
Shares of Dyne Therapeutics stock opened at $12.05 on Friday. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -3.38 and a beta of 1.11. The company has a fifty day moving average of $14.58 and a 200-day moving average of $25.27. Dyne Therapeutics, Inc. has a 52-week low of $11.18 and a 52-week high of $47.45.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. Piper Sandler decreased their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $46.00 target price on the stock. BMO Capital Markets assumed coverage on shares of Dyne Therapeutics in a research note on Wednesday. They issued an “outperform” rating and a $50.00 price target for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $48.85.
View Our Latest Stock Report on DYN
Institutional Investors Weigh In On Dyne Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new position in Dyne Therapeutics in the 3rd quarter worth $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics in the 3rd quarter worth about $36,000. US Bancorp DE increased its stake in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after acquiring an additional 1,212 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Dyne Therapeutics in the 4th quarter worth about $50,000. Finally, KBC Group NV increased its stake in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after acquiring an additional 978 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.
Dyne Therapeutics Company Profile
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
- Five stocks we like better than Dyne Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Canadian Penny Stocks: Can They Make You Rich?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.